Members of the conserved ubiquilin (UBQLN) family of ubiquitin (Ub) chaperones harbor an antipodal UBL (Ub-like)-UBA (Ubassociated) domain arrangement and participate in proteasome and autophagosome-mediated protein degradation. Mutations in a proline-rich-repeat region (PRR) of UBQLN2 cause amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD); however, neither the normal functions of the PRR nor impacts of ALS-associated mutations within it are well understood. In this study, we show that ALS mutations perturb UBQLN2 solubility and folding in a mutation-specific manner. Biochemical impacts of ALS mutations were additive, transferable to UBQLN1, and resulted in enhanced Ub association. A Drosophila melanogaster model for UBQLN2-associated ALS revealed that both wild-type and ALS-mutant UBQLN2 alleles disrupted Ub homeostasis; however, UBQLN2 ALS mutants exhibited age-dependent aggregation and caused toxicity phenotypes beyond those seen for wild-type UBQLN2. Although UBQLN2 toxicity was not correlated with aggregation in the compound eye, aggregation-prone UBQLN2 mutants elicited climbing defects and neuromuscular junctions (NMJ) abnormalities when expressed in neurons. An UBA domain mutation that abolished Ub binding also diminished UBQLN2 toxicity, implicating Ub binding in the underlying pathomechanism. We propose that ALS-associated mutations in UBQLN2 disrupt folding and that both aggregated species and soluble oligomers instigate neuron autonomous toxicity through interference with Ub homeostasis.
Introduction
The proteotoxicity hypothesis for neurodegeneration emerged from the histologic characterization of several diseases, including Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) (1) . These heterogeneous conditions are collectively referred to as proteinopathies, in which pathology is characterized by aggregates of disease-specific proteins in affected tissues of the central nervous system. The potential importance of proteotoxicity mechanisms in ALS was recognized during studies of the first identified ALS gene, superoxide dismutase 1 (SOD1), which accounts for $20% of familial ALS (fALS) cases (2) . Mutant SOD1 proteins assume toxic folds, disrupt intracellular regulation, and kill motor neurons through neuron autonomous and neuron non-autonomous mechanisms (3) (4) (5) . More recently, mutations in the nuclear RNA-binding proteins, TDP-43 and FUS/TLS, were identified in ALS, with most disease mutations occurring in low-complexity regions of the proteins, resulting in a proclivity for aggregation (6) (7) (8) (9) (10) (11) (12) (13) . Furthermore, cytosolic aggregation of wild-type TDP-43 is observed in affected brain and spinal cord of >90% of sporadic ALS (sALS) cases, establishing TDP-43 inclusion pathology among the most reliable histopathologic markers of non-SOD1 ALS (14) . Hexanucleotide repeat expansions in a non-coding region of C9ORF72-the most common genetic cause of ALS-may also promote neurodegeneration, in part, through production of toxic dipeptide repeat proteins [reviewed in (15) ].
The toxicity of ALS disease proteins may result from burdened cellular pathways related to protein trafficking and degradation (16, 17) . Indeed, mutations in genes that regulate protein homeostasis have been identified in ALS and other neurodegenerative diseases, including optineurin (OPTN) and Tank-binding kinase 1 (TBK1), which participate in a common pathway to regulate autophagy (18, 19) ; valosin-containing protein (VCP, p97 in mouse) and p62/SQSTM1, which are dual mediators of proteasomal and autophagosomal protein degradation (20) (21) (22) ; and additional genes involved in endosome trafficking and membrane remodeling, including CHMP2B, Alsin, and VAPB [reviewed in (23) ]. Of relevance to this study, mutations in Ub chaperone ubiquilin 2 (UBQLN2) cause X-linked forms of ALS/ FTD (24) . UBQLN2, belongs to a family of UBQLN proteins that are thought to participate in both proteasomal and autophagosomal protein degradation (25) (26) (27) . UBQLN2
ALS mutants accumulate in cytosolic aggregates of degenerating neurons, suggesting that UBQLN2-associated ALS is a bona fide proteinopathy (24, 28, 29) . Aggregation of wild-type UBQLN2 and closely related UBQLN1 is also observed in sALS, ALS-associated with C9ORF72 hexnucleotide repeat (HRE) expansions, and genetically distinct neurodegenerative diseases, implying that UBQLNs might function more generally in Ub-mediated aggregation (30, 31) . UBQLNs harbor an N-terminal UBL domain, which mediates interactions with the proteasome (27, 30, 32) and Ub-binding endosome proteins, such as EPS15 and HRS (33) , and a C-terminal UBA domain that binds to monoUb and all homotypic tetraUb chains (34, 35) . The central region of UBQLNs is comprised of a series of STI1 repeats and mediates protein-protein interactions and self-association (36) . Through their dual UBL-UBA configuration, UBQLNs are thought to mediate delivery of Ub-modified substrates to the proteasome (27, 37) . UBQLNs physically and genetically interact with proteins implicated in several neurodegenerative diseases, including TDP-43 (38, 39) , presenilin (40, 41) , amyloid precursor protein (42) , and polyQ expansions (43) . These findings lend circumstantial support to the idea that wild-type UBQLNs are important participants in neurodegenerative processes.
Most clinically validated ALS-associated mutations in UBQLN2 occur in a functional orphan proline-rich-repeat (PRR) adjacent to the UBA domain that is not found in any other UBQLN ortholog. UBQLN2 ALS 
Results

Differential impacts of ALS mutations on UBQLN2 solubility
We hypothesized that ALS mutations in the UBQLN2-specific PRR (Fig. 1A) (Fig. 1B) .
To investigate whether the biochemical impacts of ALS mutations are additive we constructed an UBQLN2 triple mutant harboring P506T, P509S, and P525S mutations (UBQLN2
P3X
) and an UBQLN2 quadruple mutant harboring P497H, P506T, P509S, and P525S mutations (UBQLN2 P4X ).
Whereas individual P506T, P509S, or P525S mutations had marginal impacts, UBQLN2 P3X showed dramatically reduced solubility and increased ubiquitylation. As would be expected from the inclusion of the phenotypically strong P497H mutation, UBQLN2 P4X showed a further reduction of solubility as well as increased ubiquitylation (Fig. 1B) . We surmise that ALS mutations impact UBQLN2 solubility and ubiquitylation to different extents and that these effects are additive.
UBA domain mutation uncouples UBQLN2
P497H ubiquitylation and insolubility UBQLN1 and UBQLN2 are highly similar with the notable exception of the UBQLN2-specific PRR (Fig. 1A) . A second region of sequence divergence between UBQLN1 and UBQLN2 exists at the amino-termini of the proteins, which is the basis for commercially available antibodies that can distinguish between them. Notably, UBQLN2 harbors two conserved PXXP motifs in experiments. We found that Myc-UBQLN1 was more enriched in the insoluble phase (pellet) than Myc-UBQLN2, indicating that despite sharing, greater than 70% amino acid identity, UBQLN1 and UBQLN2 are biochemically distinct (Fig. 1E , Supplementary Material, Fig. S1B ). To determine whether ALS mutations could influence ubiquitylation or solubility of UBQLN1, we measured the ubiquitylation and solubility of a UBQLN1-UBQLN2 chimera harboring the amino terminus of UBQLN1 and the PRR/UBA domain of UBQLN2, either with or without the P497H mutation (Fig. 1D) . These experiments revealed that the UBQLN1 N -UBQLN2 C/P497H chimera was substantially more Ub-modified than UBQLN1
N -UBQLN2 C/WT (Fig. 1E ) and that the UBQLN1 N -UBQLN2 C/P497H chimera was less soluble than UBQLN1 N -UBQLN2 C/WT , indicating that the P497H mutation is sufficient to decrease UBQLN1 as well as UBQLN2 solubility. Next, we disrupted the UBA domains by installing a single point mutation, F594A in UBQLN2 (denoted UBA*). The UBA* mutation abolished Ub association of UBQLN2 P497H (Fig. 1E ) and increased its solubility slightly (Fig. 1F) . Interestingly, the UBA* mutation did not rescue the insolubility of UBQLN2 P4X (Fig. 1F ). These findings suggest that UBQLN2 PRR mutants aggregate through Ubbinding dependent and Ub-binding independent mechanisms. , we tested its Ub association in GST pulldown assays. As shown in Supplementary Material, Figure S4A , GST-UBQLN2 P3X also exhibited increased association with Ub-agarose beads. We conclude that ALS mutations affect the affinity or avidity of UBQLN2 for Ub. The increased Ub association and immunoreactivity of UBQLN2 P497H and UBQLN2 P4X could be due to folding defects that expose antibody epitopes and/or alter the oligomerization status of UBQLN2. To investigate potential folding differences we carried out limited proteolysis assays using E. coli expressed GST-tagged UBQLN2 proteins. UBQLN2 P3X and UBQLN2 P4X were hypersensitive to chymotryptic cleavage relative to UBQLN2 WT , UBQLN2 P497H and UBQLN2
ALS mutations alter UBQLN2 folding and Ub binding
P525S
, which showed similar sensitivity to the enzyme ( Fig. 3C and D) . We infer that the folding of UBQLN2 is altered by the P3X or P4X mutations and that the P497H or P525S mutations may have more subtle impacts on folding that are not readily revealed by chymotryptic digestion.
Biochemical characterization of UBQLN2
ALS mutants in The cells were lysed with RIPA buffer, and the soluble fractions were immunoprecipitated with a-Myc antibody. Input, unbound and IP fractions were immunoblotted with a-Myc, a-UBQLN2, a-Ub, a-TDP43 (control) and a-HDAC6 (control) antibodies. (C) UBQLN2 -/-MEFs were transfected with the indicated Myc-UBQLN2 constructs, lysed in RIPA buffer, and the soluble fractions immunoprecipitated with UBQLN2 antibodies targeting either the amino terminus of UBQLN2 or middle region of UBQLN1/2. Soluble, insoluble, and immunoprecipitated proteins (bottom panels) were immunoblotted with indicated UBQLN2 antibodies.
corresponding increase in coprecipitated Ub (Fig. 4B ). This experiment also confirmed that UBQLN2 P497H and UBQLN2
P4X
are Ub modified (Fig. 4B, accompanied by photoreceptor neuron defects, including fused and missing rhabdomeres that were not observed in GMR > 2X-UBQLN2 WT flies (Fig. 5A ). Eye phenotypes were even more apparent in recombinant GMR > UBQLN2 lines expressing two copies of UBQLN2 and GMR driver. In addition to showing bristle loss, homozygous GMR > UBQLN2 P497H and GMR > UBQLN2 P525S flies exhibited hyperpigmented eye patches that were both more numerous and larger than those observed in homozygous GMR > UBQLN2 WT flies and never observed in homozygous GMR-Gal4 controls, though these flies exhibited a mild rougheye phenotype as previously described (56) (Fig. 5B) . Remarkably, homozygous GMR > UBQLN2 P4X flies manifested neither bristle loss nor eye patches, indicating that the eye toxicity of UBQLN2 is not directly linked to aggregation potential. The Ub-binding defective UBQLN2 UBA * mutant also failed to elicit eye patches or bristle loss, indicating that eye toxicity requires Ub binding (Fig. 5B and data not shown).
Genetic interactions between UBQLN2 and other ALS genes
We crossed homozygous GMR > UBQLN2 WT , and GMR > UBQLN2 P4X flies were digested with increasing amounts of chymotrypsin for 5 min. After separation by SDS-PAGE, the proteins were immunoblotted with a-UBQLN2 antibodies.
colocalized with Ub. UBQLN2 P525S exhibited an intermediate staining profile, with both diffuse staining and cytosolic punctae observed. As expected, UBQLN2 P4X showed even more dramatic cytosolic punctae that were colocalized with Ub (Fig. 6B,  Supplementary Material, Fig. S8 ).
Given that aging is a risk factor for ALS, we assessed UBQLN2 aggregation at weekly intervals for up to one month posteclosion. UBQLN2
WT and UBQLN2 P497H exhibited minimal aggregation in 0-day-old flies ( Fig. 6C) , whereas, UBQLN2 P4X was already highly aggregated at this early time point. UBQLN2 P497H aggregates were observable at 7-days post-eclosion, whereas UBQLN2 WT aggregates were observable beginning at day 14.
However, UBQLN2 WT aggregation never reached the levels seen for UBQLN2 P497H and UBQLN2 P4X , even in 28-day-old flies. These results suggest that intraneuronal UBQLN2 aggregation increases with age and that ALS mutations accelerate this process. Finally, to gain insights into the molecular composition of UBQLN2 aggregates we costained brains of Elav > UBQLN2 flies with a-UBQLN2 and antibodies against the Ub-binding protein p62 which plays an important role in protein degradation via proteasome and the autophagy pathways (59-61). Using 14-dayold flies that display prominent UBQLN2 pathology we found that UBQLN2 P4X aggregates were intensely stained by a-p62
antibodies, suggesting that UBQLN2 P4X strongly recruits p62 (Fig. 6D, Supplementary Material, Fig. S9 ). Although p62 pathology was less prominent in Elav > UBQLN2 P497H flies, colocalization between UBQLN2 P497H and p62 was still frequently observed. Rare UBQLN2 WT aggregates also stained positive for p62. In sum, UBQLN2 ALS mutants elicit histopathology in fly brain reminiscent of UBQLN staining pathology in ALS patient tissues, with the degree of cytoplasmic aggregation correlating roughly to the extent of insolubility seen in mammalian cells.
Neuronal expression of UBQLN2 causes climbing defects and lethality
To ascertain impacts of ALS mutations on motor behavior we crossed flies homozygous for UAS-UBQLN2 transgenes on both 2 nd and 3 rd chromosomes (see Materials and Methods) to an Elav driver and measured climbing potential of the F1 progeny at different ages. Both UBQLN2 P497H and UBQLN2 P525S elicited climbing defects that were significantly worse than those elicited by expression of UBQLN2 WT (Fig. 7A) , supporting enhanced toxicity for these ALS mutants. Climbing defects in UBQLN2 P497H flies were accompanied by alterations in neuromuscular junction (NMJ) morphology that included increased numbers of mature boutons, and features that were also seen in UBQLN2 P4X flies (Fig. 7B, Supplementary Material, Fig. S10 ). By contrast, UBQLN2 WT had no effect on the number or size of mature boutons but caused a significant decrease in satellite boutons relative to Elav controls. , despite being severely aggregation prone, elicits milder toxicity.
Ub-binding contributes to the neurotoxic potential of UBQLN2
Finally, to determine whether Ub binding contributes to the neurotoxic potential of UBQLN2, we measured climbing behavior of flies expressing UBQLN2 UBA * and the UBQLN2 P497H/UBA * compound mutant under control of Elav (Fig. 7C) . Elav > UBQLN2 P497H/ UBA * flies showed significantly better climbing ability than Elav > UBQLN2 P497H flies, suggesting that Ub binding contributes to the neurotoxicity of this ALS mutant ( Fig. 7D and E) .
Immunostaining studies further revealed that UBQLN2 P497H/UBA * was less aggregation prone than UBQLN2 P497H in Drosophila neurons (Fig. 7F) . The combined findings establish enhanced toxicity of UBQLN2 ALS mutants and suggest that Ub binding contributes to their neurotoxicity in vivo.
Discussion
In this study, we have characterized biochemical properties of wild-type and ALS-mutant UBQLN2 proteins and constructed Drosophila models to understand phenotypic impacts of disease-associated mutations in the UBQLN2 PRR. We have shown that ALS mutations exert non-identical effects on UBQLN2 solubility and folding and cause mutation-and tissuespecific toxicities in Drosophila. Our findings further implicate Ub binding as a central feature of UBQLN2 pathomechanisms. The clustering of ALS mutations within or proximal to the functional-orphan PRR domain imply that such mutations interfere with cellular processes that are unique to UBQLN2 and/or initiate toxic folds that disrupt cellular regulation through GOF mechanisms. We tested five clinical mutations (P497H, P497S, P506T, P509S, P525S) and found that only P497H consistently promoted insolubility beyond wild-type levels (Fig. 1) . His substitutions at disease codons Pro-506 and Pro-509 did not elicit the same changes in solubility as the P497H mutation, indicating that both the nature of the substitution (i.e. Pro to His) and its position within the PRR critically determine the extent of insolubility (data not shown). Although individual P506T, P509S, and P525S mutations had minor effects on solubility, their combination in UBQLN2 P3X (P506T, P509S, and P525S) and UBQLN2 P4X (P497H, P506T, P509S, and P525S) proteins led to severe reductions in solubility and patent neuronal aggregation ( Figs 1B and 6B) . Although results using compound mutants must be interpreted cautiously, these findings suggest that ALS mutations elicit additive or synergistic effects on UBQLN2 folding. The increased immunoreactivity of UBQLN2
P497H
, UBQ LN2
P3X
, and UBQLN2 P4X with antibodies directed against aminoterminal epitope tags and endogenous UBQLN2 peptides supports the notion that localized mutations in the PRR lead to global changes in UBQLN2 folding ( Fig. 2A-C) , which is further bolstered by the enhanced chymotryptic sensitivity of UBQLN2 P3X and UBQLN2 P4X in cell culture ( Fig. 3C and D ) and fly heads (Fig. 4C) . Interestingly, we observed age-dependent increases in chymotryptic cleavage of UBQLN2 proteins expressed in fly heads, and aging dependent increases in the aggregation of UBQLN2 WT and UBQLN2 P497H in fly neurons (Fig. 6C) suggesting that UBQLN2 folding is sensitive to the aging , and Elav > UBQLN2 P497H/UBA * flies was measured at 10-days post-eclosion as described in Materials and
Methods. A minimum of 50 flies were used for each genotype. Unpaired t-test was used for statistical analysis. (*P < 0.05, ***P < 0.0001, *****P < 0.0001). (E) Non-climbers from (D) were arbitrarily defined as flies that climbed < 1 cm. (Table 1 and Fig. 7A and B) ;
whereas eye-directed expression of UBQLN2 P497H and UBQLN2 P525S elicited severe bristle loss and hyperpigmented eye patches (Fig. 5, Supplementary Material, Fig. S6 (Fig. 7B, Supplementary Material,   Fig. S10 ). From the combined findings, we propose that soluble, partially misfolded UBQLN2 oligomers and/or microaggregates are the primary toxic species as has been proposed for neurodegeneration-associated mutants of SOD1 and Huntingtin (62) (63) (64) (65) . UBQLN2 macroaggregates, amplified by the artificial P4X mutation, also contribute to neurodegeneration, perhaps through pathways that are distinct from those initiated by soluble proteins (Fig. 8) . Critical pathways mediating each mode of UBQLN2 toxicity should be illuminated through genetic modifier screens using the suite of Drosophila UBQLN2 ALS models described here.
Materials and Methods
Plasmids and antibodies
A list of plasmids used in this study is provided in Table 2 . PCRgenerated hUBQLN1 and hUBQLN2 cDNAs were subcloned into the BglII-KpnI sites and EcoRI-XhoI sites of pCMV-Myc, respectively, and expressed as C-terminal fusions to an N-terminal Myc tag. The UBQLN1-UBQLN2 chimera was generated by amplifying a cDNA fragment from nt 1396 (relative to start ATG) to the 3' end of the UBQLN2 ORF using a forward primer (5'-CCACTGAAGCCCCGGGCCTGATTCCGAGC-3') containing a silent SmaI site. The PCR fragment was subcloned into the SmaI-KpnI sites of pCMV-Myc: UBQLN1. The UBQLN1-UBQLN2 fusion was made within a region of extended identity (Ala-Pro-Gly), just upstream of the UBQLN2 PRR. UBA* (F594A) and UBL* (I75T) mutants contain inactivating mutations in the UBA and UBL domains, respectively. All mutants were generated using a QuickChange mutagenesis strategy. Cell culture and transfection HEK 293T cells were cultured in DMEM supplemented with 10% fetal bovine serum and 100 U/ml penicillin/streptomycin in a humidified 5% CO 2 incubator. HEK 293T cells or MEFs were transfected by Lipofectamine 3000 (Invitrogen). MEFs were isolated from 14.5-day C57BL/6J embryo and immortalized by transfection with a plasmid encoding with SV40 large T antigen. UBQLN2 -/-MEFs were generated using a CRISPR-Cas9 vector 
Ub-agarose binding assay
Ub-agarose beads (Boston Biochem, Cambridge, MA) were incubated with lysates from either HEK 293T cells expressing WT or ALS mutations of Myc-UBQLN2, or Escherichia coli (Origami) expressing WT or ALS mutations of GST-UBQLN2. After overnight incubation in 1% TX-100 IP buffer, Ub-agarose beads were washed with 1% TX-100 buffer three times. The washed beads were boiled in SDS-loading buffer for 5 min. Ub-agarose beads binding proteins were analysed by Western blotting with a-Myc or a-GST antibodies, or staining with Coomassie blue.
Limited proteolysis
GST-tagged UBQLN2 proteins were purified from E. coli extracts using GST affinity chromatography. A total of 50 ng of each protein in 10 ll was digested with increasing amounts of chymotrypsin (0.008 lg/ml to 0.032 lg/ml, final volume, Sigma) for 5 min or 0.008 lg/ml chymotrypsin for the indicated length of time at room temperature. Limited proteolysis of UBQLN2 proteins expressed under control of GMR was performed by incubating 1: 100 dilution of detergent extracts from 10 fly heads in total volume of 20 ll in the presence of 0.001 lg/ml or 0.002 lg/ml chymotrypsin for 5 min. Digestion was terminated by addition of Laemmli loading dye and boiling at 95 C for 5 min.
The digested proteins were analysed by Western blotting or staining with Coomassie blue.
Generation of transgenic flies
The w1118 strain was used as wild-type control and host for transgenesis. For transgene insertion at specific genomic sites, we used fly strains in which the phiC31 integrase is inserted on the X chromosome and attP landing sites is located in 51D (2nd chromosome) or 86Fb (3rd chromosome). Drosophila Kozak sequence (caacATG) was designed in the UBQLN2 forward primer to facilitate expression. UBQLN2 open-reading frames were subcloned into the pUASTattB vector using EcoRI and XhoI. White gene is used to screen for positive transformants, which shows red eyes in w1118 background. The WT, P497H, and P525S lines were injected by Rainbow Transgenic Flies, Inc.; the P4X, UBA*, and P497H/UBA* lines were injected and balanced by BestGene. UBQLN2 (2X) lines were made through genetic crossing from the two original lines. To drive transgene expression in tissue-specific manner, we used the pan-neuronal diver Gal4-Elav/CyO (Bloomingston Stock FBst0008765) and the eye specific Gal4-ninaE.GMR (Bloomington Stock FBst0001104). Second chromosome recombinant GMR > UBQLN2 and Elav > UBQLN2 fly lines were made using standard methods.
Drosophila climbing
Flies were maintained with the standard cornmeal-yeast medium (Nutri-Fly (BF), Genesee scientific) supplemented with propionic acid and all crosses were performed at 23 C. Climbing assay was modified from methods described previously (66) . Climbing ability was measured by tapping $10 flies to the bottom of a graduated testing vial and taking a time-delayed photograph taken 5 or 10 s later. Position of individual flies was P497H, P506T, P509S, P525S, R581* determined using the PointPicker plugin in Image J. Data showing velocity of each individual fly were graphed as scattered plots with mean climbing distance and SEM. Unpaired t-test with Welch's correction were used for statistical analysis for different groups of flies. Non-climbers were arbitrarily defined as flies that climbed < 1 cm and plotted separately.
NMJ assay
Third-instar, wandering larvae from the F1 generation were rinsed in ice-cold PBS (Lonza, 17-512F) and dissected along the dorsal midline. All tissues except the brain and nerves were removed to expose the muscles and NMJs. The dissected larval pelt was fixed in 4% paraformaldehyde in PBS for 20 min at room temperature. The larval pelts were given a wash with PBS followed by blocking with 5% Normal Goat Serum (NGS) (Abcam ab7481) in 0.1% PBST (0.1% Triton-X-100 in PBS). Following blocking, the larval pelts were probed with primary antibodies overnight at 4 C. They were then washed several times with 0.1% PBST followed by incubation with secondary antibodies for 2 h at room temperature, subsequently followed by washes with 0.1% PBST. Larvae were then mounted onto slides using Prolong Gold (Invitrogen, P36930) mounting media. Confocal images were acquired using Zeiss LSM 710 confocal microscope and a 60x oil objective was used to image the NMJs. Both primary and secondary antibody solutions were prepared in 5% NGS in 0.1% PBST. For primary antibodies, the following dilutions were used: 1: 100 Cy3-conjugated goat anti-HRP (Jackson ImmunoResearch, 123-165-021); 1: 100 mouse anti-DLG 4F3 (DSHB). For secondary antibodies, the following antibody dilutions were used: 1: 250 Alexa Fluor 647-conjugated antiPhalloidin (Invitrogen, A22287); 1: 500 goat anti-mouse Alexa Fluor 488 (Invitrogen, A-11029). For the analyses, NMJs innervating muscle 4 on segments A2-A3 were imaged and analysed for synaptic bouton quantification. Mature boutons are defined as boutons that are included in a chain of two or more boutons. Satellite boutons are defined as a single bouton that is not included in a chain of boutons, and instead, sprout off of a mature bouton or branch. The groups were compared using Unpaired Student t-test on GraphPad Prism software. P-value less than 0.05 was considered statistically significant.
UBQLN2 solubility and ubiquitylation assay
Fly lysates were prepared by homogenizing 10 fly heads (5 from each gender) in 90 ll of 4X sample loading buffer containing 250 mM Tris-HCl (pH 6.8), 5% SDS, 10% glycerol and 5% 2-mercaptoethanol by pestle. 10% of protein lysate were resolved in 10% SDS-PAGE gel and detected via standard Western blotting procedure. For soluble/insoluble extraction, fly heads were homogenized in RIPA buffer at volume of 10 ll per head. Soluble fraction was taken after spinning in a microcentrifuge at 14 000 rpm for 10 min. The insoluble pellet was washed twice before re-suspension in buffer and boiled for 20 min. To perform IP analysis, RIPAsoluble fractions were incubated with UBQLN2 antibody and protein A/G agarose beads. After washing with 0.2% TX-100/PBS for three times, the IP samples were analysed with Western blot.
Microscopy
The protocol for fly immunohistochemistry was adapted from previously published protocol (66) . Adult fly brains were dissected using a pair of fine forceps in PBS (or 0.3% TX-100 in PBS), fixed, blocked with NGS, and stained with primary antibodies at 1: 500 dilution for two overnights at 4 C. After subsequent secondary antibody staining, DAPI was added for the nuclear staining. Images were acquired using a Nikon A1 confocal microscope using either a 10X lens or a 60X oil lens. Eye pictures were acquired using Leica S9 i Stereomicroscope.
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